-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

386 A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET)Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Session: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis
Hematology Disease Topics & Pathways:
Clinical Trials, Acquired Marrow Failure Syndromes, Bone Marrow Failure Syndromes, Clinical Research, Diseases, Myeloid Malignancies
Sunday, December 12, 2021: 9:45 AM

Francesca Palandri, MD, PhD1*, Nicola Vianelli, MD2,3*, David M Ross, MBBS, PhD, FRACP, FRCPA4*, Tara Cochrane, MBBS, FRCPA, FRACP5, Steven W Lane, MD, PhD6, Stephen R Larsen, MBBS PhD FRACP FRCPA7, Aaron T. Gerds, MD, MS8, Anna B. Halpern, MD9, Jake Shortt, FRACP, FRCPA, PhD10, James M. Rossetti, DO11, Kristen M. Pettit12, Amber Jones, MA13*, Jennifer Peppe, BS14*, Georges Natsoulis, Ph.D.15*, Willis Navarro, MD16, Wan-Jen Hong, MD16, William S. Stevenson, MBBS, PhD17, Claire N. Harrison, DM18, Moshe Talpaz, MD12 and Hugh Young Rienhoff Jr., MD19

1Institute of Hematology "L. & A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy
2Azienda Ospedaliero-Universitaria S.Orsola-Malpighi di Bologna, Bologna, Italy
3Institute of Hematology "L. & A. Seragnoli", Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni 15, Bologna, Italy
4Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia
5Department of Haematology, Gold Coast University Hospital, Southport, Australia
6QIMR Berghofer Medical Research Institute, Brisbane, Australia
7Institute of Haematology, Royal Prince Alfred Hospital, Sydney, NSW, Australia
8Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
9Department of Medicine, Division of Hematology, University of Washington, Seattle, WA
10Monash Haematology, Monash Health, Clayton, VIC, Australia
11UPMC Hillman Cancer Center, Pittsburgh, PA
12Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
13Imago Biosciences Inc., Chilton Polden, GBR
14Imago BioSciences, Inc., San Carlos, CA
15Imago Biosciences, Inc., San Carlos, CA
16Imago BioSciences, San Carlos, CA
17Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia
18Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
19Imago Biosciences, San Francisco

Many patients with ET are resistant to or intolerant of current standards of care (SOC) - hydroxyurea (HU), interferon, anagrelide - underscoring the need for novel therapies with distinct modes of action that reduce the risk of thrombosis, improve the patient’s experience and favorably alter the natural history. Lysine-specific demethylase-1 (LSD1) is an enzyme critical for the self-renewal potential of malignant cells and hematopoietic differentiation, e.g., LSD1 licenses progenitors to mature into megakaryocytes, a cell central to ET pathogenesis. Bomedemstat is an orally active LSD1 inhibitor that reduced peripheral cell counts, splenomegaly, inflammatory cytokines, mutant cell burdens and improved survival in mouse models of MPNs (Kleppe et al. 2015; Jutzi et al. 2018). IMG-7289-CTP-201 is a global, open-label, Phase 2b study of bomedemstat taken once daily for 24+ weeks in patients with ET who are resistant to or intolerant of at least one SOC treatment (NCT04254978).

Key eligibility criteria include patients who require cytoreduction, a platelet count >450 x 109/L, hemoglobin ≥10 g/dL and absolute neutrophil count ≥0.5 x 109/L. Key objectives are safety and response, defined as platelets ≤400 x 109/L without new thromboembolism or disease progression. Exploratory endpoints include durability of response, reduction in WBCs, changes in mutant allele frequencies (MAF), and symptom improvement. All patients start at a dose of 0.6 mg/kg/d that is titrated to a target platelet count of 200-400 x 109/L.

At data cut-off (15July'21), 30 patients have enrolled. Baseline median age was 68 (42-84) years with 33% males; 77% were resistant to or intolerant of HU, 10% to anagrelide, 7% to interferon, and 3% each to busulfan and ruxolitinib. The Day 1 (washout up to 28 days) mean platelet, WBC and hemoglobin values were 876 x 109/L (457-2220), 9.7 x 109/L (4.4-30.6), and 13.0 g/dL (9.4-16.5) respectively. Among all patients, median MPN10 total symptom score (TSS) at baseline was 16 (0-74); TSS >10 was observed in 63% (19/30); median 30 (11-74). Genotyping by sequencing at screening (N=32) revealed mutations in JAK2 (50%) and CALR (44%) with a wide distribution of MAFs (1-85%). All patients were wild-type at the MPL locus, two patients were “triple-negatives” and five patients had copy number neutral loss of heterozygosity. Non-driver mutations were present in 31% (10/32) including EZH2, ASXL1, SF3B1 and TP53.

Median time on study is 16 weeks (0-41). Platelet count was reduced in 92% (24/26) of patients treated for more than 6 weeks with 81% (21/26) achieving a platelet count of ≤400 x 109/L. Of the 9/30 (30%) patients with a Day 1 WBC count ≥10 x 109/L, 89% (8/9) had a WBC count <10 x 109/L while on treatment (see graphs). All patients maintained a stable hemoglobin (see graph). In patients with baseline TSS >10 (19/30), at Week 12, 77% (10/13) had decreased scores and 46% (6/13) demonstrated >10-point improvement. Of patients resequenced (261 genes) at Week 24 (N=6), mutant allele frequencies were stable and no new mutations were detected. Enrollment is on-going; additional clinical and genetic data will be presented.

The most common (reported by >15% of patients) treatment-emergent AEs deemed related were dysgeusia (40%), fatigue, thrombocytopenia (without bleeding), constipation, and diarrhea (each 17%). Six AEs ≥Grade 3 were reported in 5 patients, with 2 (dysgeusia and constipation) deemed related to bomedemstat by the Investigator. Two unrelated SAEs were reported: a lung infection and a pulmonary embolus. Four patients discontinued treatment, three due to AEs (nausea, dysgeusia x 2) and one withdrew consent on Day 1. Similar to an ongoing MF study of bomedemstat (NCT03136185), there have been no safety signals, DLTs, or deaths related to drug. At the time of data cut-off, 87% (26/30) of patients remain on study.

To date, in a majority of patients who were resistant or intolerant to at least one standard of care, bomedemstat has shown to be well-tolerated, reduce platelets, improve symptoms, and moderate WBC counts while maintaining hemoglobin. For those patients treated for at least 6 weeks, 81% achieved a complete peripheral blood count remission without evidence of disease progression. The mutation burden remained stable despite high molecular risk mutations.

Based on this promising data, a Phase 3 study of bomedemstat for the treatment of ET is being planned.

Disclosures: Ross: Bristol Myers Squib: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Keros Therapeutics: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Lane: BMS: Consultancy, Research Funding; Geron: Consultancy; Astellas: Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria; Novartis: Consultancy. Gerds: Constellation: Consultancy; AbbVie: Consultancy; Brystol Myers Squibb: Consultancy; Sierra Oncology: Consultancy; Novartis: Consultancy; PharmaEssentia: Consultancy; Incyte: Research Funding; Constellation: Research Funding; Krtos: Research Funding; CTI Biopharma: Research Funding; Imago: Research Funding; Accutate: Research Funding. Halpern: Novartis: Research Funding; Bayer: Research Funding; Tolero Pharmaceuticals: Research Funding; Agios Pharmaceuticals: Research Funding; Abbvie: Consultancy; Gilead: Research Funding; Agios: Consultancy; Imago Pharmaceuticals: Research Funding; Jazz Pharmaceuticals: Research Funding; Nohla Therapeutics: Research Funding; Pfizer: Research Funding. Shortt: Astellas: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Amgen: Research Funding; Astex: Research Funding. Jones: Imago BioSciences: Current Employment, Current equity holder in publicly-traded company. Peppe: Imago BioSciences: Current Employment, Current equity holder in publicly-traded company. Natsoulis: Imago BioSciences: Current Employment, Current equity holder in publicly-traded company. Navarro: Imago BioSciences: Current Employment, Current equity holder in publicly-traded company. Hong: Imago BioSciences: Current Employment, Current equity holder in publicly-traded company; Genentech, Inc.: Ended employment in the past 24 months. Harrison: Promedior: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Gilead Sciences: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AOP Orphan Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sierra Oncology: Honoraria; Geron: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Galacteo: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Keros: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Constellation Pharmaceuticals: Research Funding; Incyte Corporation: Speakers Bureau; Shire: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Talpaz: Imago: Consultancy; Celgene: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Takeda: Other: Grant/research support ; Constellation: Membership on an entity's Board of Directors or advisory committees. Rienhoff: Imago BioSciences: Current Employment, Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.

*signifies non-member of ASH